1Lau DT, Khokhar MF, Doo E, el. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology, 2000,32: 828-834.
2Nafa S, Ahmed S, Tavan D, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology,2000,32:1078-1088.
3Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119:172-180,2000
4Leung NW,Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology, 2001,33:1527-1532.
5Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive(precore mutant)chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology, 1999,29: 889-896.
6Santantonio T, Mazzola M, lacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12months with lamivudine. J Hepatol, 2000,32: 300-306.
7Suzuki Y, Kumada H, Ikeda K, et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol, 1999,30: 743-748.
8Chen SI, An Y, Qin LY, et al. Lamivudine treatment in patients with severely cirrhosis. J Gastroenterol Hepatol,2001,161 (Suappl) A: 328.
9Lee HC, Suh DJ. Lamivudine therapy for decompensated liver cirrhosis related to hepatitis B virus infection. Intervirology, 2003,46:388-393.
10Manolakopoulos S, Karatapains S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decmpensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol, 2004,99:57-63.
